General Federal Contracts — March 26, 2026

Three HHS contracts totaling $792M provide multi-year funding through 2029 for tobacco studies (Westat $505M, 42% outlayed), biotech (ATI $161M), and COVID assays (PPD $126M, 18% outlayed).

AATD's $138M obligated (89% outlayed) with $423M base+options potential via set-aside underscores small biz leverage in federal IT through 2026.

Acacia ($832M, 94% outlayed) and ATI dominate value but as nonprofits offer no direct investment vectors despite $184M options upside.

Low early outlays in new awards (ATI $240k/161M; PPD $23M/126M) signal execution delays over 4-6 year periods.

COVID-focused R&D (PPD $126M) vulnerable to priority shifts; long horizons (to 2029) expose all to funding cliffs.

Heavy subawards (Acacia 119/$285M; Westat 12/$27M) risk delays/disputes in legal/health services.

$713M unexercised options across Westat ($455M), AATD ($285M), Acacia ($184M) offer 40% total upside if funded.

HHS/BARDA biotech/COVID R&D ($287M) and VA SDVOSB IT set-asides position for follow-on awards.

45% of value ($792M) in NAICS 54171x R&D for tobacco, biotech, COVID via cost-plus/T&M structures through 2029.

47% ($970M) in legal/IT for migrants (Acacia) and vets (AATD), with high outlays indicating locked-in spend.

{"entity"=>"Westat Inc.", "reason"=>"$505M PATH Study with $455M options and 2028 horizon offers largest upside in health R&D.", "trigger"=>"options exercised or outlays >$300M"}

{"entity"=>"PPD Development LP", "reason"=>"$126M BARDA COVID R&D to 2029 at risk from priority shifts but fully committed.", "trigger"=>"HHS COVID budget cuts or accelerated outlays"}

{"entity"=>"AATD LLC", "reason"=>"89% outlay on $138M VA IT with $285M options; SDVOSB for follow-ons.", "trigger"=>"additional VA obligations or set-aside wins"}